Incidence and mortality of second primary malignancies after lymphoma: a population-based analysis

References

• Armitage J, Gascoyne R, Lunning M, et al. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):1–13. doi: 10.1016/s0140-6736(16)32407-2.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Ayyappan S, Maddocks K. Novel and emerging therapies for B cell lymphoma. J Hematol Oncol. 2019;12(1):82. doi: 10.1186/s13045-019-0752-3.
   PubMed Web of Science ®Google Scholar
• Travis L, Demark Wahnefried W, Allan J, et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10(5):289–301. doi: 10.1038/nrclinonc.2013.41.
   PubMed Web of Science ®Google Scholar
• Kumar V, Ailawadhi S, Bojanini L, et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019;9(10):75. doi: 10.1038/s41408-019-0237-1.
   PubMedGoogle Scholar
• Morton L, Curtis R, Linet M, et al. Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010;28(33):4935–4944. doi: 10.1200/jco.2010.29.1112.
   PubMed Web of Science ®Google Scholar
• Furman RR, Byrd JC, Owen RG, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. 2021;35(11):3201–3211. doi: 10.1038/s41375-021-01252-y.
   PubMed Web of Science ®Google Scholar
• Franklin J, Eichenauer D, Becker I, et al. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis. Cochrane Database Syst Rev. 2017;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.
   PubMedGoogle Scholar
• Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med. 2008;59(1):237–250. doi: 10.1146/annurev.med.59.060906.220345.
   PubMedGoogle Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi: 10.1016/s0140-6736(17)33326-3.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Fan Y, Wang Y, et al. China national lung cancer screening guideline with low-dose computed tomography (2018 version). Zhongguo Fei Ai Za Zhi. 2018;21(2):67–75. doi: 10.3779/j.issn.1009-3419.2018.02.01.
   PubMedGoogle Scholar
• Brenner H, Altenhofen L, Stock C, et al. Prevention, early detection, and overdiagnosis of colorectal cancer within 10 years of screening colonoscopy in Germany. Clin Gastroenterol Hepatol. 2015;13(4):717–723. doi: 10.1016/j.cgh.2014.08.036.
   PubMed Web of Science ®Google Scholar
• Bauer AT, Gorzelanny C, Gebhardt C, et al. Interplay between coagulation and inflammation in cancer: limitations and therapeutic opportunities. Cancer Treat Rev. 2022;102:102322. doi: 10.1016/j.ctrv.2021.102322.
   PubMed Web of Science ®Google Scholar
• Bond D, Huang Y, Fisher J, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 2020;34(12):3197–3205. doi: 10.1038/s41375-020-0987-6.
   PubMed Web of Science ®Google Scholar
• Leslie L. Novel therapies for follicular lymphoma and other indolent Non-Hodgkin lymphomas. Curr Treat Options Oncol. 2021;22(12):111. doi: 10.1007/s11864-021-00909-1.
   PubMed Web of Science ®Google Scholar
• Beiggi S, Johnston J, Seftel M, et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer. 2013;109(5):1287–1290. doi: 10.1038/bjc.2013.381.
   PubMed Web of Science ®Google Scholar
• Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev. 2009;61(4):290–302. doi: 10.1016/j.addr.2009.02.005.
   PubMed Web of Science ®Google Scholar
• Benjamini O, Jain P, Trinh L, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56(6):1643–1650. doi: 10.3109/10428194.2014.957203.
   PubMed Web of Science ®Google Scholar
• Joelsson J, Wästerlid T, Rosenquist R, et al. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Adv. 2022;6(8):2657–2666. doi: 10.1182/bloodadvances.2021006369.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Zheng G, Sud A, et al. Second primary cancers in non-Hodgkin lymphoma: family history and survival. Int J Cancer. 2020;146(4):970–976. doi: 10.1002/ijc.32391.
   PubMed Web of Science ®Google Scholar
• Hu S, Ren S, Cai Y, et al. Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of wnt-β-catenin-STAT3 signaling. Cell Death Differ. 2022;29(3):642–656. doi: 10.1038/s41418-021-00880-2.
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhan L, Huang K, et al. The functions and clinical significance of circRNAs in hematological malignancies. J Hematol Oncol. 2020;13(1):138. doi: 10.1186/s13045-020-00976-1.
   PubMed Web of Science ®Google Scholar
• Miller K, Nogueira L, Mariotto A, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi: 10.3322/caac.21565.
   PubMed Web of Science ®Google Scholar
• Sands J, Tammemägi M, Couraud S, et al. Lung screening benefits and challenges: a review of the data and outline for implementation. J Thorac Oncol. 2021;16(1):37–53. doi: 10.1016/j.jtho.2020.10.127.
   PubMed Web of Science ®Google Scholar
• Pashayan N, Antoniou A, Ivanus U, et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol. 2020;17(11):687–705. doi: 10.1038/s41571-020-0388-9.
   PubMed Web of Science ®Google Scholar
• Nakasone E, Askautrud H, Kees T, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012;21(4):488–503. doi: 10.1016/j.ccr.2012.02.017.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhou X, Wang X. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol. 2021;14(1):125. doi: 10.1186/s13045-021-01134-x.
   PubMed Web of Science ®Google Scholar
• Pesce S, Greppi M, Grossi F, et al. PD/1-PD-Ls checkpoint: insight on the potential role of NK cells. Front Immunol. 2019;10:1242. doi: 10.3389/fimmu.2019.01242.
   PubMed Web of Science ®Google Scholar